Abstract
Original language | English |
---|---|
Pages (from-to) | 3099-3111 |
Number of pages | 13 |
Journal | Journal of Chemical Information and Modeling |
Volume | 54 |
Issue number | 11 |
DOIs | |
Publication status | Published - 2014 |
Keywords
- Amino acids
- Functional groups
- Heavy ions
- Neurodegenerative diseases
- Peptides
- Pharmacodynamics
- Adverse side effects
- Chemical equations
- Long term stability
- Mushroom tyrosinase
- Pharmacophore modeling
- Serendipitous discovery
- Tyrosinase inhibition
- Tyrosinase inhibitors
- Plants (botany)
- biological product
- enzyme inhibitor
- ligand
- monophenol monooxygenase
- oligopeptide
- antagonists and inhibitors
- chemistry
- drug development
- metabolism
- molecular docking
- protein conformation
- sequence alignment
- Biological Products
- Drug Discovery
- Enzyme Inhibitors
- Ligands
- Molecular Docking Simulation
- Monophenol Monooxygenase
- Oligopeptides
- Protein Conformation
- Sequence Alignment
Access to Document
Fingerprint
Dive into the research topics of 'Serendipitous discovery of short peptides from natural products as tyrosinase inhibitors'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of Chemical Information and Modeling, Vol. 54, No. 11, 2014, p. 3099-3111.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Serendipitous discovery of short peptides from natural products as tyrosinase inhibitors
AU - Hsiao, Nai-Wan
AU - Tseng, Tien-Sheng
AU - Lee, Yu-Ching
AU - Chen, Wang-Chuan
AU - Lin, Hui-Hsiung
AU - Chen, Yun-Ru
AU - Wang, Yeng-Tseng
AU - Hsu, Hung-Ju
AU - Tsai, Keng-Chang
N1 - 被引用次數:3 Export Date: 28 March 2016 CODEN: JCISD 通訊地址: Tsai, K.-C.; National Research Institute of Chinese Medicine, Ministry of Health and WelfareTaiwan 化學物質/CAS: monophenol monooxygenase, 9002-10-2; Biological Products; Enzyme Inhibitors; Ligands; Monophenol Monooxygenase; Oligopeptides 參考文獻: Costin, G.E., Hearing, V.J., Human skin pigmentation: Melanocytes modulate skin color in response to stress (2007) FASEB J., 21, pp. 976-994; Alexis, A., Barbosa, V.H., (2013) Skin of Color: A Practical Guide to Dermatologic Diagnosis and Treatment, , Springer: Berlin, Heidelberg; Piamphongsant, T., Treatment of melasma: A review with personal experience (1998) Int. J. Dermatol., 37, pp. 897-903; Cavalieri, E.L., Li, K.M., Balu, N., Saeed, M., Devanesan, P., Higginbotham, S., Zhao, J., Rogan, E.G., Catechol orthoquinones: The electrophilic compounds that form depurinating DNA adducts and could initiate cancer and other diseases (2002) Carcinogenesis, 23, pp. 1071-1077; Kim, Y.J., Uyama, H., Tyrosinase inhibitors from natural and synthetic sources: Structure, inhibition mechanism and perspective for the future (2005) Cell. Mol. Life Sci., 62, pp. 1707-1723; Eisenhofer, G., Tian, H., Holmes, C., Matsunaga, J., Roffler-Tarlov, S., Hearing, V.J., Tyrosinase: A developmentally specific major determinant of peripheral dopamine (2003) FASEB J., 17, pp. 1248-1255; Chang, T.S., An updated review of tyrosinase inhibitors (2009) Int. J. Mol. Sci., 10, pp. 2440-2475; Slominski, A., Tobin, D.J., Shibahara, S., Wortsman, J., Melanin pigmentation in mammalian skin and its hormonal regulation (2004) Physiol. Rev., 84, pp. 1155-1228; Pan, T., Li, X., Jankovic, J., The association between Parkinson's disease and melanoma (2011) Int. J. Cancer, 128, pp. 2251-2260; Asanuma, M., Miyazaki, I., Ogawa, N., Dopamine- or L-DOPA-induced neurotoxicity: The role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease (2003) Neurotox Res., 5, pp. 165-176; Seo, S.Y., Sharma, V.K., Sharma, N., Mushroom tyrosinase: Recent prospects (2003) J. Agric. Food Chem., 51, pp. 2837-2853; Elsner, P., Maibach, H.I., Cosmeceuticals: Drugs vs. Cosmetics (2000) Cosmetic Science and Technology Series, 23. , Marcel Dekker: New York; Maeda, K., Fukuda, M., Arbutin: Mechanism of its depigmenting action in human melanocyte culture (1996) J. Pharmacol. Exp. Ther., 276, pp. 765-769; Schurink, M., Van Berkel, W.J., Wichers, H.J., Boeriu, C.G., Novel peptides with tyrosinase inhibitory activity (2007) Peptides, 28, pp. 485-495; Germanas, J.P., Wang, S., Miner, A., Hao, W., Ready, J.M., Discovery of small-molecule inhibitors of tyrosinase (2007) Bioorg. Med. Chem. Lett., 17, pp. 6871-6875; Smith, M.T., Yager, J.W., Steinmetz, K.L., Eastmond, D.A., Peroxidase-dependent metabolism of benzene' s phenolic metabolites and its potential role in benzene toxicity and carcinogenicity (1989) Environ. Health Perspect., 82, pp. 23-29; Rossi, L., Moore, G.A., Orrenius, S., O'Brien, P.J., Quinone toxicity in hepatocytes without oxidative stress (1986) Arch. Biochem. Biophys., 251, pp. 25-35; DeCaprio, A.P., The toxicology of hydroquinone - Relevance to occupational and environmental exposure (1999) Crit. Rev. Toxicol., 29, pp. 283-330; Fuyuno, I., Spotlight turns on cosmetics for Asian skin (2004) Nature, 432, p. 938; Girelli, A.M., Mattei, E., Messina, A., Tarola, A.M., Inhibition of polyphenol oxidases activity by various dipeptides (2004) J. Agric. Food Chem., 52, pp. 2741-2745; Abu Ubeid, A., Zhao, L., Wang, Y., Hantash, B.M., Short-sequence oligopeptides with inhibitory activity against mushroom and human tyrosinase (2009) J. Invest. Dermatol., 129, pp. 2242-2249; Kim, H., Choi, J., Cho, J.K., Kim, S.Y., Lee, Y.S., Solid-phase synthesis of kojic acid -tripeptides and their tyrosinase inhibitory activity, storage stability, and toxicity (2004) Bioorg. Med. Chem. Lett., 14, pp. 2843-2846; Morita, H., K, T., Kobata, H., Gonda, A., Takeya, K., Itokawa, H., Pseudostellarins D -F, new tyrosinase inhibitory cyclic peptides from Pseudostellaria heterophylla (1994) Tetrahedron, pp. 9975-9982; Shimizu, K., Kondo, R., Sakai, K., Inhibition of tyrosinase by flavonoids, stilbenes and related 4-substituted resorcinols: Structure - Activity investigations (2000) Planta Med., 66, pp. 11-15; Zheng, Z.P., Cheng, K.W., To, J.T., Li, H., Wang, M., Isolation of tyrosinase inhibitors from Artocarpus heterophyllus and use of its extract as antibrowning agent (2008) Mol. Nutr. Food Res., 52, pp. 1530-1538; Tajima, R., Oozeki, H., Muraoka, S., Tanaka, S., Motegi, Y., Nihei, H., Yamada, Y., Nihei, K., Synthesis and evaluation of bibenzyl glycosides as potent tyrosinase inhibitors (2011) Eur. J. Med. Chem., 46, pp. 1374-1381; Bao, K., Dai, Y., Zhu, Z.B., Tu, F.J., Zhang, W.G., Yao, X.S., Design and synthesis of biphenyl derivatives as mushroom tyrosinase inhibitors (2010) Bioorg. Med. Chem., 18, pp. 6708-6714; Yi, W., Cao, R., Peng, W., Wen, H., Yan, Q., Zhou, B., Ma, L., Song, H., Synthesis and biological evaluation of novel 4-hydroxybenzaldehyde derivatives as tyrosinase inhibitors (2010) Eur. J. Med. Chem., 45, pp. 639-646; Casanola-Martin, G.M., Marrero-Ponce, Y., Tareq Hassan Khan, M., Torrens, F., Perez-Gimenez, F., Rescigno, A., Atom- and bond-based 2D TOMOCOMD-CARDD approach and ligand-based virtual screening for the drug discovery of new tyrosinase inhibitors (2008) J. Biomol. Screen., 13, pp. 1014-1024; Ryu, Y.B., Westwood, I.M., Kang, N.S., Kim, H.Y., Kim, J.H., Moon, Y.H., Park, K.H., Kurarinol, tyrosinase inhibitor isolated from the root of Sophora flavescens (2008) Phytomedicine, 15, pp. 612-618; Marrero-Ponce, Y., Khan, M.T., Casanola-Martin, G.M., Ather, A., Sultankhodzhaev, M.N., Garcia-Domenech, R., Torrens, F., Rotondo, R., Bond-based 2D TOMOCOMD-CARDD approach for drug discovery: Aiding decision-making in "in silico" selection of new lead tyrosinase inhibitors (2007) J. Comput. Aided Mol. Des., 21, pp. 167-188; Ahmad, V.U., Ullah, F., Hussain, J., Farooq, U., Zubair, M., Khan, M.T., Choudhary, M.I., Tyrosinase inhibitors from Rhododendron collettianum and their structure-activity relationship (SAR) studies (2004) Chem. Pharm. Bull. (Tokyo), 52, pp. 1458-1461; Zheng, Z.P., Zhu, Q., Fan, C.L., Tan, H.Y., Wang, M., Phenolic tyrosinase inhibitors from the stems of Cudrania cochinchinensis (2011) Food Funct., 2, pp. 259-264; Kim, J.M., Ko, R.K., Jung, D.S., Kim, S.S., Lee, N.H., Tyrosinase inhibitory constituents from the stems of Maackia fauriei (2010) Phytother. Res., 24, pp. 70-75; Yi, W., Cao, R., Wen, H., Yan, Q., Zhou, B., Ma, L., Song, H., Discovery of 4-functionalized phenyl-O-beta-D-glycosides as a new class of mushroom tyrosinase inhibitors (2009) Bioorg. Med. Chem. Lett., 19, pp. 6157-6160; Momtaz, S., Mapunya, B.M., Houghton, P.J., Edgerly, C., Hussein, A., Naidoo, S., Lall, N., Tyrosinase inhibition by extracts and constituents of Sideroxylon inerme L. Stem bark, used in South Africa for skin lightening (2008) J. Ethnopharmacol., 119, pp. 507-512; Yoon, N.Y., Eom, T.K., Kim, M.M., Kim, S.K., Inhibitory effect of phlorotannins isolated from Ecklonia cava on mushroom tyrosinase activity and melanin formation in mouse B16F10 melanoma cells (2009) J. Agric. Food Chem., 57, pp. 4124-4129; Morimura, K., Yamazaki, C., Hattori, Y., Makabe, H., Kamo, T., Hirota, M., A tyrosinase inhibitor, Daedalin A, from mycelial culture of Daedalea dickinsii (2007) Biosci., Biotechnol., Biochem., 71, pp. 2837-2840; Yi, W., Cao, R., Wen, H., Yan, Q., Zhou, B., Wan, Y., Ma, L., Song, H., Synthesis and biological evaluation of helicid analogues as mushroom tyrosinase inhibitors (2008) Bioorg. Med. Chem. Lett., 18, pp. 6490-6493; Matos, M.J., Santana, L., Uriarte, E., Delogu, G., Corda, M., Fadda, M.B., Era, B., Fais, A., New halogenated phenylcoumarins as tyrosinase inhibitors (2011) Bioorg. Med. Chem. Lett., 21, pp. 3342-3345; John, S., Thangapandian, S., Sakkiah, S., Lee, K.W., Potent BACE-1 inhibitor design using pharmacophore modeling, in silico screening and molecular docking studies (2011) BMC Bioinf., 12, p. S28; Sarma, R., Sinha, S., Ravikumar, M., Kishore Kumar, M., Mahmood, S.K., Pharmacophore modeling of diverse classes of p38 MAP kinase inhibitors (2008) Eur. J. Med. Chem., 43, pp. 2870-2876; Tukamoto, T.T., Taniguchi, T., Comparison of inhibitory effect of various chemical agents on tyrosinase activity by manometric method (1958) J. Invest. Dermatol., 30, pp. 305-310; Jergil, B., Lindbladh, C., Rorsman, H., Rosengren, E., Inactivation of human tyrosinase by cysteine. Protection by dopa and tyrosine (1984) Acta Derm. Venereol., 64, pp. 155-157; Ghani, U., Ullah, N., New potent inhibitors of tyrosinase: Novel clues to binding of 1,3,4-thiadiazole-2(3H)-thiones, 1,3,4-oxadiazole-2(3H)-thiones, 4-amino-1,2,4-triazole-5(4H)-thiones, and substituted hydrazides to the dicopper active site (2010) Bioorg. Med. Chem., 18, pp. 4042-4048; Schurink, M., (2007) Peptides As Inhibitors of Lipoxygenase and Tyrosinase, , Thesis, Wageningen University, Wageningen, The Netherlands; Ryckaert, J.-P., Ciccotti, G., Berendsen, H.J.C., Numerical integration of the cartesian equations of motion of a system with constraints: Molecular dynamics of n-alkanes (1977) J. Comput. Phys., 23, pp. 327-341; Darden, T., York, D., Pedersen, L., Particle mesh Ewald: An N· log(N) method for Ewald sums in large systems (1993) J. Chem. Phys., 98, pp. 10089-10092; Laskowski, R.A., Swindells, M.B., LigPlot+: Multiple ligand-protein interaction diagrams for drug discovery (2011) J. Chem. Inf. Model., 51, pp. 2778-2786; Wallace, A.C., Laskowski, R.A., Thornton, J.M., LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions (1995) Protein Eng., 8, pp. 127-134; Brooks, B.R., Bruccoleri, R.E., Olafson, B.D., States, D.J., Swaminathan, S., Karplus, M., CHARMM: A program for macromolecular energy, minimization, and dynamics calculations (1983) J. Comput. Chem., 4, pp. 187-217; Li, J., Ehlers, T., Sutter, J., Varma-O'Brien, S., Kirchmair, J., CAESAR: A new conformer generation algorithm based on recursive buildup and local rotational symmetry consideration (2007) J. Chem. Inf. Model., 47, pp. 1923-1932; Piao, L.Z., Park, H.R., Park, Y.K., Lee, S.K., Park, J.H., Park, M.K., Mushroom tyrosinase inhibition activity of some chromones (2002) Chem. Pharm. Bull. (Tokyo), 50, pp. 309-311; Takahashi, M., Takara, K., Toyozato, T., Wada, K., A novel bioactive chalcone of Morus australis inhibits tyrosinase activity and melanin biosynthesis in B16 melanoma cells (2012) J. Oleo Sci., 61, pp. 585-592
PY - 2014
Y1 - 2014
N2 - Tyrosinase, which is the crucial copper-containing enzyme involved in melanin synthesis, is strongly associated with hyperpigmentation disorders, cancer, and neurodegenerative disease; thus, it has attracted considerable interest in the fields of medicine and cosmetics. The known tyrosinase inhibitors show numerous adverse side effects, and there is a lack of safety regulations governing their use. As a result, there is a need to develop novel inhibitors with no toxicity and long-term stability. In this study, we use molecular docking and pharmacophore modeling to construct a reasonable and reliable pharmacophore model, called Hypo 1, that could be used for identifying potent natural products with crucial complementary functional groups for mushroom tyrosinase inhibition. It was observed that, out of 47 263 natural compounds, A5 structurally resembles a dipeptide (WY) and natural compound B16 is the equivalent of a tripeptide (KFY), revealing that the C-terminus tyrosine residues play a key role in tyrosinase inhibition. Tripeptides RCY and CRY, which show high tyrosinase inhibitory potency, revealed a positional and functional preference for the cysteine residue at the N-terminus of the tripeptides, essentially determining the capacity of tyrosinase inhibition. CRY and RCY used the thiol group of cysteine residues to coordinate with the Cu ions in the active site of tyrosinase and showed reduced tyrosinase activity. We discovered the novel tripeptide CRY that shows the most striking inhibitory potency against mushroom tyrosinase (IC50 = 6.16 μM); this tripeptide is more potent than the known oligopeptides and comparable with kojic acid-tripeptides. Our study provides an insight into the structural and functional roles of key amino acids of tripeptides derived from the natural compound B16, and the results are expected to be useful for the development of tyrosinase inhibitors. (Chemical Equation Presented). © 2014 American Chemical Society.
AB - Tyrosinase, which is the crucial copper-containing enzyme involved in melanin synthesis, is strongly associated with hyperpigmentation disorders, cancer, and neurodegenerative disease; thus, it has attracted considerable interest in the fields of medicine and cosmetics. The known tyrosinase inhibitors show numerous adverse side effects, and there is a lack of safety regulations governing their use. As a result, there is a need to develop novel inhibitors with no toxicity and long-term stability. In this study, we use molecular docking and pharmacophore modeling to construct a reasonable and reliable pharmacophore model, called Hypo 1, that could be used for identifying potent natural products with crucial complementary functional groups for mushroom tyrosinase inhibition. It was observed that, out of 47 263 natural compounds, A5 structurally resembles a dipeptide (WY) and natural compound B16 is the equivalent of a tripeptide (KFY), revealing that the C-terminus tyrosine residues play a key role in tyrosinase inhibition. Tripeptides RCY and CRY, which show high tyrosinase inhibitory potency, revealed a positional and functional preference for the cysteine residue at the N-terminus of the tripeptides, essentially determining the capacity of tyrosinase inhibition. CRY and RCY used the thiol group of cysteine residues to coordinate with the Cu ions in the active site of tyrosinase and showed reduced tyrosinase activity. We discovered the novel tripeptide CRY that shows the most striking inhibitory potency against mushroom tyrosinase (IC50 = 6.16 μM); this tripeptide is more potent than the known oligopeptides and comparable with kojic acid-tripeptides. Our study provides an insight into the structural and functional roles of key amino acids of tripeptides derived from the natural compound B16, and the results are expected to be useful for the development of tyrosinase inhibitors. (Chemical Equation Presented). © 2014 American Chemical Society.
KW - Amino acids
KW - Functional groups
KW - Heavy ions
KW - Neurodegenerative diseases
KW - Peptides
KW - Pharmacodynamics
KW - Adverse side effects
KW - Chemical equations
KW - Long term stability
KW - Mushroom tyrosinase
KW - Pharmacophore modeling
KW - Serendipitous discovery
KW - Tyrosinase inhibition
KW - Tyrosinase inhibitors
KW - Plants (botany)
KW - biological product
KW - enzyme inhibitor
KW - ligand
KW - monophenol monooxygenase
KW - oligopeptide
KW - antagonists and inhibitors
KW - chemistry
KW - drug development
KW - metabolism
KW - molecular docking
KW - protein conformation
KW - sequence alignment
KW - Biological Products
KW - Drug Discovery
KW - Enzyme Inhibitors
KW - Ligands
KW - Molecular Docking Simulation
KW - Monophenol Monooxygenase
KW - Oligopeptides
KW - Protein Conformation
KW - Sequence Alignment
U2 - 10.1021/ci500370x
DO - 10.1021/ci500370x
M3 - Article
SN - 1549-9596
VL - 54
SP - 3099
EP - 3111
JO - Journal of Chemical Information and Modeling
JF - Journal of Chemical Information and Modeling
IS - 11
ER -